This review concerns five specific packages for the delivery of computerised cognitive behaviour therapy (CCBT) accessed via a referral from a general practitioner (GP): three for depression (Beating the Blues, COPE and Overcoming Depression), one for panic/phobia (FearFighter) and one for obsessive-compulsive disorder (OCD) (OCFighter, previously known as BTSteps).
This guidance should be read in the context of the Clinical Guidelines on depression, anxiety and OCD). 1.1 This recommendation has been replaced by recommendations in the two depression clinical guidelines (CG90 and CG91) published in October 2009. 1.2 This recommendation has been replaced by recommendations in the two depression clinical guidelines (CG90 and CG91) published in October 2009. 1.3 This recommendation has been replaced by the generalised anxiety disorder and panic disorder guideline (CG113), published in January 2011, and by the social anxiety disorder guideline (CG159), published in May 2013. 1.4 OCFighter (previously known as BTSteps) is not recommended as an option for delivering CBT in the management of OCD. 1.5 People currently using OCFighter, whether as routine therapy or as part of a clinical trial, should have the option to continue on therapy until the person, or the GP and/or specialist, consider it appropriate to stop. Organization 1992 and American Psychiatric Association 1994, respectively).
2.2
Depression refers to a wide range of mental health problems characterised by the absence of positive affect (a loss of interest and enjoyment in ordinary things and experiences), low mood and a range of associated emotional, cognitive, physical and behavioural symptoms. Depression varies in severity, and individuals with major depression can be differentiated into those with mild, moderate and severe disease on the basis of symptom severity and impairment of functioning.
2.3
There are several anxiety disorders including generalised anxiety disorder (GAD), panic disorder, phobias (agoraphobia without panic disorder, agoraphobia with panic disorder, social phobias and specific [isolated] phobias) and OCD. Symptoms of depression and anxiety more often than not co-exist.
There is also often overlap between panic and phobias, with many people having both. 2.4 OCD is clinically distinct from the other anxiety disorders. Obsessions are defined as being recurrent persistent thoughts, impulses or images that are intrusive and inappropriate and that cause marked anxiety or distress.
Compulsions are repetitive, purposeful and ritualistic behaviours or mental acts, performed in response to obsessional intrusion, to a set of rigidly prescribed rules. 2.5 Depression and anxiety have a broad impact and are associated with poor quality of life, occupational disadvantage, impairment in interpersonal and family relationships, and suicide. Diagnosable depressive disorders are implicated in 40-60% of suicide attempts, with 10-15% of people with major depressive disorders eventually committing suicide. ICD-10 uses an agreed list of ten depressive symptoms and divides the common form of major depressive episode into four groups: not depressed, mildly depressed, moderately depressed and severely depressed.
Computerised cognitive behaviour therapy for depression and anxiety (TA97) 2.6 In 2000, the Psychiatric Morbidity Survey conducted by the Office of Population Censuses and Surveys found prevalences, per 1000 people aged 16-74 years in England and Wales, of 187 for mixed anxiety and depression, 95 for GAD and 62 for depressive episode. Corresponding figures for phobia, panic disorder and OCD were 38, 13 and 38, respectively. In 1995, 9 in every 100 people with mental health problems who consulted their GP were referred to specialist services for assessment, advice and treatment. 2.7 There is wide variation in the recorded prevalence and incidence of anxiety and depression. However, many individuals do not seek treatment, and both anxiety and depression are often undiagnosed. Recognition of anxiety disorders by GPs is often poor, and only a small minority of people who experience anxiety disorders actually undergo treatment.
2.8
Anxiety and depression are currently managed by drug therapy or a range of 'psychotherapies' (a generic term to cover the predominantly talk-based psychological therapies in their various forms), or both. There is, however, wide variation in care practices among individual GPs. In addition to prescribed medication, support can include access to self-help material, exercise and referral for occupational therapy, vocational rehabilitation and counselling.
Primary care counselling services are now being established in many primary care trusts (PCTs) in England. After an appropriate assessment, the counsellor can offer short-term therapeutic interventions for people with mild and moderate anxiety or depression or refer individuals with severe depression and anxiety to more specialised services. In 'stepped-care' approaches, the individual is given basic interventions at the start of therapy and is stepped up to more complex interventions as and when necessary. Although careful risk assessment is required, such approaches can theoretically minimise the need for more specialised services.
2.9
A broad range of psychotherapies is provided by a number of different health professionals in the NHS. The range includes CBT, behaviour therapy, interpersonal therapy, problem-solving therapy, non-directive counselling and short-term psychodynamic psychotherapy.
2.10
CBT is a generic term that refers to the pragmatic combination of concepts and techniques from cognitive therapy and behavioural therapy. Both of these use structured approaches based on the assumption that prior learning is currently Computerised cognitive behaviour therapy for depression and anxiety (TA97) having maladaptive consequences. The purpose of therapy is to reduce distress or unwanted behaviour by undoing this learning or by providing new, more adaptive learning experiences. The way in which CBT is delivered varies, depending on the individual's needs.
2.11
The effectiveness of CBT is supported by evidence from randomised controlled trials (RCTs). For many diagnostic groups, controlled trials indicate that approximately 50% of individuals with depression experience clinically important improvement, which is similar to outcomes achieved with antidepressant drugs.
2.12
The behavioural component of CBT aims to reduce dysfunctional emotions and behaviour by altering the individual's behaviour and the factors that control it.
Methods used may involve behavioural experiments to test irrational thoughts, graded exposure to feared situations, target setting and activity scheduling. The cognitive component attempts to reduce dysfunctional emotions and behaviour by altering individual appraisals and thinking patterns. Methods used include discussion of the cognitive model, diary keeping (developing awareness of thoughts, affect, behaviour and physical symptoms), examination of evidence for and against dysfunctional beliefs, cognitive rehearsal and the development of skills to challenge negative thoughts and dysfunctional assumptions.
2.13
Anxiety disorders are commonly treated by the CBT technique of 'selfexposure' in which individuals expose themselves to situations of increasing difficulty. Individuals are asked to record their thoughts and beliefs about the exposure situation before, during and after exposure. Behavioural treatment for OCD involves exposure to whatever evokes obsessions and prevents avoidance or neutralisation of the resulting anxiety. Cognitive methods aim to challenge the obsessive thoughts.
2.14
In comparison with other psychotherapies, CBT is brief, highly structured, problem-orientated and prescriptive, and individuals are active collaborators.
The optimal length of therapy will vary among individuals. For mild and moderate depression, brief CBT of six to eight sessions over 10 to 12 weeks is usual. For moderate to severe depression, the duration is typically in the range of 16 to 20 sessions over 6 to 9 months. For anxiety the optimal range of duration of CBT is between 7 and 14 hours. For people with OCD in whom the degree of functional impairment is mild, up to 10 hours of CBT including Computerised cognitive behaviour therapy for depression and anxiety (TA97) exposure and response prevention (ERP) may be offered; for those with a higher degree of functional impairment more than 10 hours of CBT that includes ERP should be offered. CBT-trained therapists can be from a number of disciplines and may include clinical psychologists, mental health nurse specialists and psychiatrists.
2.15
There is evidence that some people prefer 'talking therapies' involving face-toface contact with the therapist rather than drug treatment. However, access to counselling and psychotherapy services is restricted by the high level of demand, the limited availability of therapists -especially in some geographical areas -and a lack of clear referral criteria and pathways.
2.16
Computerised CBT (CCBT) is included as an option in the stepped-care model presented in the NICE clinical guideline for the management of depression in primary and secondary care and in the NICE clinical guideline for the management of anxiety (panic disorder, with or without agoraphobia, and GAD) in adults in primary, secondary and community care. A guideline for OCD has been published (see Section 8 − Related guidance).
2.17
Within step 2 of the NICE clinical guideline for the management of depression in primary and secondary care, CCBT is included as a more structured treatment alternative (together with problem solving, brief CBT or counselling) to initial interventions such as exercise or guided self-help.
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The technology The technology 3.1 CCBT is a generic term that is used to refer to a number of methods of delivering CBT via an interactive computer interface. It can be delivered on a personal computer, over the Internet or via the telephone using interactive voice response (IVR) systems. As with CBT, pre-therapy assessment is recommended to ensure that people are suitable for therapy, and individuals require ongoing monitoring and support. It is suggested that a wide range of health or social care personnel could be used to facilitate the sessions. Several CCBT packages are currently available. Each has been developed for a specific target group or groups and uses different CBT algorithms. The personnel required to implement CCBT can vary from psychiatrist to practice nurse and the length of therapist's time will also vary depending on the programme.
3.2
Beating the Blues (Ultrasis plc) is a CBT-based package for people with anxiety and/or depression. It consists of a 15-minute introductory video and eight 1-hour interactive computer sessions. The sessions are usually at weekly intervals and are completed in the routine care setting (that is, GP practice).
Homework projects are completed between sessions and weekly progress reports are delivered to the GP or other healthcare professional at the end of each session. These progress reports include anxiety and depression ratings and reported suicidality. No minimum reading age is specified.
3.3 COPE (ST Solutions Ltd) is a CBT-based system designed to help people with non-severe depression. COPE was developed as an IVR plus workbook-based system. It is also available as a network version (netCOPE). It assumes a minimum reading age of 11 years. People can phone as and when they wish.
COPE is a 3-month programme with five main treatment modules. Suicide assessment questions are included and people are urged to contact their doctor if suicidal ideation or plans are experienced. 3.4 Overcoming Depression: a Five Areas Approach (a Calipso product from Media Innovations Ltd) is a CD-ROM-based CBT system for people with depression.
The system consists of six sessions of about 45-60 minutes each. The sessions are delivered in a mixture of text, cartoon illustrations, animation, interactive text, sound and video. It assumes a minimum reading age of 9-12 years for all but one module. The CD-ROM training materials suggest that a practitioner Computerised cognitive behaviour therapy for depression and anxiety (TA97) reviews the person's use of the disc on three occasions over the course. Sessions are completed on a weekly basis. 3.5 FearFighter (ST Solutions Ltd) is a CBT-based package for phobic, panic and anxiety disorders. FearFighter was originally developed for a stand-alone personal computer (standaloneFF) but was later developed for use on the Internet (netFF). It is also available in a short version for educational purposes (FFeducation). FearFighter assumes a minimum reading age of 11 years.
FearFighter is divided into nine steps. Therapist contact for FearFighter is brief, with 5 minutes before the session and up to 15 minutes after each session. For netFF, therapist contact is by telephone or e-mail. 3.6 BTSteps (ST Solutions Ltd) (now called OCFighter) is designed to help people with OCD by helping them plan and carry out CBT on a day-to-day basis.
BTSteps was developed as an IVR system plus workbook. It assumes a minimum reading age of 11 years. An Internet version is under development and will obviate the need for IVR and workbook. Helpline support is provided. BTSteps is divided into nine steps.
3.7
The availability of CCBT programmes permits increased treatment flexibility, especially for individuals who do not want, or who are not suitable for, drug therapy or who do not wish to interact with a therapist. Computerised delivery of CBT can also be used to support therapist sessions. CCBT may also be of benefit to individuals with, for example, agoraphobia and social phobias because it can be delivered at home. Minimal therapist appointment time is necessary for the types of CCBT that can be conducted at home, and the therapy has 24-hour availability for the individual to access at his or her convenience. CCBT systems can also make it possible for users to repeat sessions if they wish.
3.8
The total annual operating costs depend on whether the purchase price includes a dedicated computer system, technical support, training and clinical support. Fourteen studies (six RCTs, two non-RCTs and six non-comparative studies)
were identified for the five packages included in the review. Some of trials had considerably more female than male participants, particularly in the case of depression. In most studies, the mean age of patients was in the range 30-45 years. In the majority of trials, patients were included who were also taking medications for their particular disorder. Multiple outcomes using multiple measures were collected in the trials.
Depression Depression
Beating the Blues Beating the Blues
Two RCTs (one unpublished) and one non-comparator trial (unpublished) were used in the assessment of Beating the Blues. However, the unpublished RCT was marked 'academic in confidence'; hence the results are not reported in this review. The published RCT contained 274 patients at baseline assessment but pre-treatment values were recorded in only 241 patients, and only around twothirds of patients were assessed at the end of the follow-up period of 6 months.
Randomisation was stratified according to whether drug treatment was also being received. All of the trials were conducted in a primary care setting in the UK and all trials recruited patients through GP referral or screening with the General Health Questionnaire (GHQ). With regard to patient satisfaction for Beating the Blues, the published RCT found that Beating the Blues patients were significantly more satisfied (as measured on a single item) with treatment than TAU patients, although values were not reported. In the submission from the manufacturer of Beating the Blues, an unpublished paper discussing the credibility and satisfaction of the programme was included. This open trial reported that nine out of ten patients stated that they would recommend the programme to others and over half stated that it was better than any other treatment that they had received.
COPE COPE

4.1.6
Two non-comparator trials were used in the assessment of COPE (n = 39 and n = 41 patients), and the follow-up period for both was a maximum of 12 weeks. One trial was conducted in the UK and the other in both the USA and the UK, over the telephone. Recruitment for one of the studies was through self-referral and the other was through self-and healthcare professional-referral. Both trials reported information on patient history, such as duration of symptoms and previous therapy or medication. Only one of the trials gave reasons for loss to follow-up. In one of the trials, it was reported that patients felt comfortable with the system, found it easy to use and found the booklets helpful, while 75% of the 28 completers said that COPE had improved the quality of their lives. 4.1.13 Two RCTs and two non-comparator trials were used in the assessment of BTSteps. The total numbers of patients in the trials ranged from 21 to 218, with follow-up periods ranging from 14 to 22 weeks. Patient history and socioeconomic information were reported in three of the studies, but none of the trials reported reasons for loss to follow-up. Two of the trials were conducted in the UK, one in the US and Canada, and one was conducted at two centres in the US and UK. Three of the four studies used DSM-III-R criteria for diagnosis, and one used ICD-10. Both of the RCTs had methodological problems; one did not use blind assessment or did not report reasons for loss to follow-up and the other did not report the method of randomisation, use blind assessment (except for a subgroup of 41% that was rated blind at the two main time periods) and did not report reasons for loss to follow-up.
4.1.14 One RCT compared BTSteps (n = 74) with TCBT (n = 69) and relaxation (n = 75).
TCBT was found to be statistically significantly more effective than BTSteps at The Assessment Group identified one published economic evaluation. No formal analyses of cost effectiveness were included in the manufacturer submissions.
The Assessment Group developed its own economic models for the three disease areas: depression, panic/phobia and OCD. The Assessment Group reported the costs resulting from the following: licence fees, computer hardware, screening of patients for suitability, clinical support, capital overheads and training of staff. The basic principles of costing were very similar for all three products; however, the Assessment Group assumed a lower screening time for COPE. CCBT also had an impact on reducing the level of depression compared with TAU, which has consequences for use of other services.
4.2.5
The Assessment Group used utility values obtained from a study that provided data on 62 patients with BDI total scores and Euroqol EQ-5D. Mean scores for three depression categories were estimated: mild to moderate 0.78 (SD 0.20), moderate to severe 0.58 (SD 0.31) and severe 0.38 (SD 0.32). For the minimal category, it was assumed that the mean score was 0.88 (SD 0.22).
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4.2.6
Mean package costs (cost per patient) for Beating the Blues were estimated at £219.30 for a single-copy licence and £104.62 for a 20-copy licence. These estimates come with large ranges, reflecting the uncertainties around the unit costs and the expected numbers of treated patients at practice level. The transition probabilities for Beating the Blues were estimated from changes on the BDI in the pivotal trial.
4.2.7
The CQG of Beating the Blues over TAU was reported as £1801 for the singlecopy licence (assumed mean number of patients treated 37.5). If the licence was to be offered to PCTs for 20 copies (assumed mean number of patients treated 750) the CQG would fall to £415. Running the model for one cycle increased the CQG to £4961. For the subgroup analysis, the results showed that the mild to moderate group had the lowest mean CQG of £1802, but there was little difference among groups.
COPE COPE
4.2.8
Two costings were undertaken for practice level licences, one assuming that the practice would provide computer access and the other assuming that patients could access the Internet from home or some other location (cost-free to the NHS). Both options included the cost for a telephone support line. The estimated mean cost per patient was £171.30 for no practice computer access and £195.86 with practice computer access. At PCT level, the cost fell to £110.53. These estimates come with large ranges, reflecting the uncertainties around the unit costs and the expected numbers of treated patients at practice level. For COPE, the transition probabilities were estimated from one of the non-comparative trials and no individual level data were available.
4.2.9
The CQG of COPE over TAU was reported as £7139 when modelled using a GP practice licence (assumed mean number of patients treated 37.5). If the licence were to be offered to PCTs (assumed mean number of patients treated 750), the CQG would fall to £3915. Limiting the model to one cycle increased the CQG to £16,469.
Computerised cognitive behaviour therapy for depression and anxiety (TA97) The Committee reviewed the data available on the clinical and cost effectiveness of CCBT for the management of depression and anxiety, having considered evidence on the nature of the condition and the value placed on the benefits of CCBT by people with depression and anxiety, those who represent them, and clinical experts. It was also mindful of the need to take account of the effective use of NHS resources.
4.3.2
The Committee noted that NICE guidelines have been published for the management of depression in primary and secondary care and for the management of anxiety (panic disorder, with or without agoraphobia, and GAD) in adults in primary, secondary and community care. Both guidelines place CCBT as an option only within step 2 of a stepped-care approach. The Committee also heard testimony from the patient and clinical experts that there are several methods available for delivering CBT in the NHS and that the comparators used in the studies reviewed had excluded some important ones such as group CBT and bibliotherapy. The Committee appreciated that CCBT would not necessarily be the best delivery method for CBT for all patients. However, the Committee heard that enabling patient choice between various methods of delivery of CBT was likely to increase the motivation to comply with treatment. The Committee was also informed by the experts that, in general, the CCBT packages being appraised could be considered as being as 'safe' as CBT in that the information and guidance delivered by these packages were similar to that given in a standard CBT approach. The experts also stated that CCBT would not be appropriate for the management of severe depression.
4.3.3
The Committee carefully considered all the comparators that had been used in the trials. The Committee heard testimony from the clinical experts that TAU was an appropriate comparator for CCBT for patients with mild and moderate depression, but that relaxation was considered an imperfect comparator for the management of panic and phobia and OCD. The Committee also noted that TCBT could be considered as an appropriate comparator for all three disease areas but took on board the issue of the lack of availability of trained therapists and consequently the long waiting times for treatment.
Computerised cognitive behaviour therapy for depression and anxiety (TA97) 4.3.4 The Committee noted that the evidence base for Beating the Blues had improved since the previous appraisal. In particular, more data relating to the single RCT had become available. The results from this RCT showed that
Depression Depression
Beating the Blues was more effective than TAU on a number of outcome measures, and the ES for the Beck Depression Inventory was particularly notable. The Committee noted some limitations in the evidence base which were only partially reflected in the uncertainty around the cost-effectiveness estimates. However, the Committee was persuaded that the evidence base was sufficient for the CQG estimate for Beating the Blues to be acceptable. 4.3.5 The Committee noted that there is no RCT evidence for COPE or Overcoming
Depression for the management of depression. Therefore, the Committee could not establish with a reasonable degree of certainty that either of these packages is a clinically or cost-effective method of treating people with depression over and above other management options such as TAU. Furthermore, it was not able to conclude that the CCBT packages for depression could be considered to be equivalent as in a 'class', because of the differences between the packages' presentation, style and complexity. 4.3.6 Therefore, on the basis of currently available data, the Committee concluded that, of the three CCBT packages for depression, only Beating the Blues could currently be recommended as an option for delivering CBT in the management of mild and moderate depression as outlined in the current NICE clinical guideline for the stepped-care management of depression in primary and secondary care (see Section 8 -Related guidance). P Panic/phobia anic/phobia 4.3.7 The Committee considered the evidence base for FearFighter for the management of panic and phobia, and noted that there was one relevant RCT that established that FearFighter was more effective than TCBT on one outcome measure, but less effective on others. 4.3.8 The Committee noted that the use of FearFighter could be considered to be cost effective versus relaxation. It was mindful, however, of the fact that the comparison of TCBT versus CCBT resulted in a CQG of £18,000 (with a sensitivity analysis increasing this to £25,000 depending on the purchasing Computerised cognitive behaviour therapy for depression and anxiety (TA97) scenario). On this basis, TCBT would be the preferred option for the management of panic/phobia. However, the Committee considered that, not only were both TCBT and CCBT to some extent effective, but also that there was substantial uncertainty in the greater effectiveness of TCBT implied by the economic model. 4.3.9 The Committee concluded that it was acceptable to consider FearFighter as an option for delivering CBT in the management of panic/phobia as outlined in the current NICE clinical guideline for the stepped-care management of anxiety (panic disorder, with or without agoraphobia, and generalised anxiety disorder) in adults in primary, secondary and community care (see Section 8 -Related guidance).
Obsessiv Obsessive-compulsiv e-compulsive disorder e disorder 4.3.10 The Committee considered the RCT evidence for BTSteps for the management of OCD in which BTSteps was compared with TCBT and relaxation. The
Committee was concerned with the methodology reported for the RCT with regard to aspects of the study design. The Committee noted that in the randomised clinical trials BTSteps was never more effective than TCBT. It also noted that patients were more satisfied with TCBT than with BTSteps. 4.3.11 Regarding the cost effectiveness the Committee noted that there were a number of scenarios modelled for purchasing BTSteps in the NHS. In all these scenarios TCBT was more cost effective than BTSteps and relaxation. Only in the scenario in which an average PCT has to purchase a bulk licence is BTSteps more cost effective than relaxation. However, the Committee did not consider that an average PCT should reasonably seek to treat a mean number of 250 patients with BTSteps when TCBT is the most cost-effective option for that PCT to deliver CBT. 4.3.12 The Committee considering both the clinical and cost-effective evidence concluded that BTSteps should not be recommended as an option for delivering CBT in the management of OCD.
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Recommendations for further research Recommendations for further research 5.1 Future studies of CCBT should be RCTs that include an ITT analysis, to take account of drop-outs, and record and report any adverse effects, including major self-harm or suicide. They should also collect appropriate information on costs and health-related quality of life -that is, data should be collected using generic preference-based measures (in conjunction with condition-specific instruments) because they facilitate the calculation of QALY. They should also attempt to identify the type of individual within any one treatment group (that is, depression, panic/phobia or OCD) most likely to benefit from CCBT.
Consideration should be given to undertaking these RCTs within a GP setting, because most patients with depression and anxiety are currently treated in this setting and patients recruited to the trials should not be self-referrers.
Consideration should also be given to whether the packages can be used effectively by patients of all ages and from all ethnic groups. The majority of consultees thought that specific RCTs that would be useful include:
pragmatic RCTs for CCBT packages in a stepped-care programme comparisons of CCBT with other self-help comparators that are currently used by this patient group, such as bibliotherapy and exercise comparisons of CCBT with placebo comparisons of CCBT with brief and longer duration TCBT as well as group TCBT head-to-head trials between the packages for depression.
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Implications for the NHS Implications for the NHS 6.1
Since the final appraisal determination was issued, NICE has carried out more detailed costing analysis to support implementation of the guidance. The following costing tools are available from the NICE website.
A national costing report, which estimates the overall resource impact associated with implementation.
A local costing template: a simple spreadsheet that can be used to estimate the local cost of implementation.
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Calculation of compliance
Compliance (%) with each measure described in the table above is calculated as follows.
Number of patients whose care is consistent with the criterion plus criterion plus number of patients who meet any e ex xception ception listed Number of patients to whom the measure measure applies x 100
Clinicians should review the findings of measurement, identify whether practice can be improved, agree on a plan to achieve any desired improvement and repeat the measurement of actual practice to confirm that the desired improvement is being achieved.
